Aplagon, a clinical-stage biotechnology company developing APAC, a first-in-class antiplatelet and anticoagulant therapeutic platform for thrombo-inflammatory diseases, announced the appointment of Carl Lindgren as Chair of its Board of Directors. His experience spanning global pharmaceutical companies, specialty pharma businesses and public and private company boards provides Aplagon with valuable expertise as it advances towards later-stage development and commercialisation. Carl takes over from current Chair, Sakari Lassila, who will remain on the Board of Directors.
Aki Prihti, CEO of Aplagon, said:
Carl’s appointment brings a rare combination of commercial, business development and strategic leadership experience that will be invaluable as we advance APAC through Phase 2 development.
"His track record of building healthcare businesses, creating partnerships and supporting growth will help us maximise the potential of APAC across multiple thrombo-inflammatory indications."
Carl Lindgren, Chair of the Board of Directors of Aplagon, commented, “Aplagon has developed a highly differentiated therapeutic platform with the potential to address significant unmet needs in thrombo-inflammatory diseases. The clinical data generated to date from many patients across several international trials, combined with APAC’s unique mechanism of action, creates compelling opportunities for future development, partnering and value creation.”
Carl brings over 30 years of leadership experience across the life sciences industry. He has held senior commercial positions, including roles at AstraZeneca, Lundbeck, Karo Healthcare, and EQL Pharma. He has scaled healthcare businesses across international markets and led major acquisitions and business development transactions. He also brings significant board experience through his current role as Chairman of the Board at Iconovo and as a board member of Biomedica Norden AB.
